Lumexa Imaging (LMRI) Competitors

$8.00 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$8.00 0.00 (0.00%)

As of 05/22/2026 04:10 PM Eastern

LMRI vs. VCYT, PRVA, HTFL, GRAL, and DFTX

Should you buy Lumexa Imaging stock or one of its competitors? MarketBeat compares Lumexa Imaging with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lumexa Imaging include Veracyte (VCYT), Privia Health Group (PRVA), Heartflow (HTFL), GRAIL (GRAL), and Definium Therapeutics (DFTX). These companies are all part of the "healthcare" industry.

How does Lumexa Imaging compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Lumexa Imaging (NASDAQ:LMRI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Veracyte has a net margin of 16.25% compared to Lumexa Imaging's net margin of 0.00%. Veracyte's return on equity of 9.07% beat Lumexa Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
Lumexa Imaging	N/A	N/A	N/A

Veracyte presently has a consensus target price of $44.83, indicating a potential downside of 0.44%. Lumexa Imaging has a consensus target price of $16.00, indicating a potential upside of 100.00%. Given Lumexa Imaging's stronger consensus rating and higher possible upside, analysts clearly believe Lumexa Imaging is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Veracyte had 8 more articles in the media than Lumexa Imaging. MarketBeat recorded 12 mentions for Veracyte and 4 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 1.20 beat Veracyte's score of 0.49 indicating that Lumexa Imaging is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lumexa Imaging	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veracyte has higher revenue and earnings than Lumexa Imaging.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	6.95	$66.35M	$1.09	41.31
Lumexa Imaging	$267.73M	2.87	N/A	N/A	N/A

Summary

Veracyte beats Lumexa Imaging on 7 of the 11 factors compared between the two stocks.

How does Lumexa Imaging compare to Privia Health Group?

Lumexa Imaging (NASDAQ:LMRI) and Privia Health Group (NASDAQ:PRVA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Privia Health Group has higher revenue and earnings than Lumexa Imaging.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lumexa Imaging	$267.73M	2.87	N/A	N/A	N/A
Privia Health Group	$2.12B	1.35	$22.92M	$0.16	142.44

94.5% of Privia Health Group shares are owned by institutional investors. 0.7% of Lumexa Imaging shares are owned by company insiders. Comparatively, 5.7% of Privia Health Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Privia Health Group has a net margin of 0.97% compared to Lumexa Imaging's net margin of 0.00%. Privia Health Group's return on equity of 2.81% beat Lumexa Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lumexa Imaging	N/A	N/A	N/A
Privia Health Group	0.97%	2.81%	1.61%

Lumexa Imaging currently has a consensus price target of $16.00, indicating a potential upside of 100.00%. Privia Health Group has a consensus price target of $31.23, indicating a potential upside of 37.04%. Given Lumexa Imaging's higher possible upside, research analysts plainly believe Lumexa Imaging is more favorable than Privia Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Privia Health Group	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79

In the previous week, Lumexa Imaging and Lumexa Imaging both had 4 articles in the media. Lumexa Imaging's average media sentiment score of 1.20 beat Privia Health Group's score of 0.76 indicating that Lumexa Imaging is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lumexa Imaging	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Privia Health Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Privia Health Group beats Lumexa Imaging on 8 of the 12 factors compared between the two stocks.

How does Lumexa Imaging compare to Heartflow?

Heartflow (NASDAQ:HTFL) and Lumexa Imaging (NASDAQ:LMRI) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Heartflow currently has a consensus price target of $37.00, suggesting a potential upside of 25.47%. Lumexa Imaging has a consensus price target of $16.00, suggesting a potential upside of 100.00%. Given Lumexa Imaging's stronger consensus rating and higher probable upside, analysts plainly believe Lumexa Imaging is more favorable than Heartflow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heartflow	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Lumexa Imaging has higher revenue and earnings than Heartflow.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heartflow	$176.03M	14.45	-$116.79M	-$3.11	N/A
Lumexa Imaging	$267.73M	2.87	N/A	N/A	N/A

Lumexa Imaging has a net margin of 0.00% compared to Heartflow's net margin of -58.42%.

Company	Net Margins	Return on Equity	Return on Assets
Heartflow	-58.42%	N/A	-20.02%
Lumexa Imaging	N/A	N/A	N/A

In the previous week, Lumexa Imaging had 2 more articles in the media than Heartflow. MarketBeat recorded 4 mentions for Lumexa Imaging and 2 mentions for Heartflow. Lumexa Imaging's average media sentiment score of 1.20 beat Heartflow's score of -0.05 indicating that Lumexa Imaging is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heartflow	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lumexa Imaging	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lumexa Imaging beats Heartflow on 8 of the 10 factors compared between the two stocks.

How does Lumexa Imaging compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Lumexa Imaging (NASDAQ:LMRI) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Lumexa Imaging has a net margin of 0.00% compared to GRAIL's net margin of -253.22%. Lumexa Imaging's return on equity of 0.00% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-253.22%	-16.42%	-14.34%
Lumexa Imaging	N/A	N/A	N/A

In the previous week, Lumexa Imaging had 2 more articles in the media than GRAIL. MarketBeat recorded 4 mentions for Lumexa Imaging and 2 mentions for GRAIL. Lumexa Imaging's average media sentiment score of 1.20 beat GRAIL's score of 0.95 indicating that Lumexa Imaging is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lumexa Imaging	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lumexa Imaging has higher revenue and earnings than GRAIL.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	19.59	-$408.35M	-$10.37	N/A
Lumexa Imaging	$267.73M	2.87	N/A	N/A	N/A

GRAIL currently has a consensus price target of $67.88, indicating a potential upside of 1.02%. Lumexa Imaging has a consensus price target of $16.00, indicating a potential upside of 100.00%. Given Lumexa Imaging's stronger consensus rating and higher probable upside, analysts clearly believe Lumexa Imaging is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Lumexa Imaging beats GRAIL on 9 of the 11 factors compared between the two stocks.

How does Lumexa Imaging compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Lumexa Imaging (NASDAQ:LMRI) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Definium Therapeutics presently has a consensus target price of $37.92, indicating a potential upside of 68.55%. Lumexa Imaging has a consensus target price of $16.00, indicating a potential upside of 100.00%. Given Lumexa Imaging's higher possible upside, analysts plainly believe Lumexa Imaging is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Lumexa Imaging's return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
Lumexa Imaging	N/A	N/A	N/A

In the previous week, Definium Therapeutics had 4 more articles in the media than Lumexa Imaging. MarketBeat recorded 8 mentions for Definium Therapeutics and 4 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 1.20 beat Definium Therapeutics' score of -0.08 indicating that Lumexa Imaging is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lumexa Imaging	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

27.9% of Definium Therapeutics shares are owned by institutional investors. 2.3% of Definium Therapeutics shares are owned by insiders. Comparatively, 0.7% of Lumexa Imaging shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lumexa Imaging has higher revenue and earnings than Definium Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
Lumexa Imaging	$267.73M	2.87	N/A	N/A	N/A

Summary

Definium Therapeutics beats Lumexa Imaging on 6 of the 11 factors compared between the two stocks.

Get Lumexa Imaging News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LMRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LMRI vs. The Competition

Export

Metric	Lumexa Imaging	Services – Health Industry	Services Sector	NASDAQ Exchange
Market Cap	$768.65M	$1.43B	$978.18M	$12.34B
Dividend Yield	N/A	N/A	5.12%	5.28%
P/E Ratio	N/A	13.09	9.25	25.66
Price / Sales	2.87	5.23	36.53	86.31
Price / Cash	N/A	3,138.58	381.82	56.67
Price / Book	N/A	4.44	4.35	7.14
Net Income	N/A	-$26.94M	-$6.42M	$335.98M
7 Day Performance	14.32%	1.35%	3.07%	4.11%
1 Month Performance	-16.67%	-5.43%	-5.06%	2.52%
1 Year Performance	N/A	N/A	48.28%	35.04%

Lumexa Imaging Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LMRI Lumexa Imaging	4.53 of 5 stars	$8.00 flat	$16.00 +100.0%	N/A	$768.65M	$267.73M	N/A	4,335	Gap Up
VCYT Veracyte	1.9448 of 5 stars	$38.90 +1.7%	$44.83 +15.3%	+65.8%	$3.05B	$517.15M	35.69	790
PRVA Privia Health Group	4.1343 of 5 stars	$23.24 +2.7%	$31.23 +34.4%	-0.3%	$2.85B	$2.25B	145.26	1,226
HTFL Heartflow	3.332 of 5 stars	$32.24 +3.3%	$37.67 +16.8%	N/A	$2.69B	$176.03M	N/A	699
GRAL GRAIL	1.4162 of 5 stars	$61.80 +2.2%	$67.88 +9.8%	+67.2%	$2.60B	$147.17M	N/A	1,360

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LMRI) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lumexa Imaging (LMRI) Competitors

LMRI vs. VCYT, PRVA, HTFL, GRAL, and DFTX

How does Lumexa Imaging compare to Veracyte?

Summary

How does Lumexa Imaging compare to Privia Health Group?

Summary

How does Lumexa Imaging compare to Heartflow?

Summary

How does Lumexa Imaging compare to GRAIL?

Summary

How does Lumexa Imaging compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMRI vs. The Competition

Lumexa Imaging Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lumexa Imaging (LMRI) Competitors

LMRI vs. VCYT, PRVA, HTFL, GRAL, and DFTX

How does Lumexa Imaging compare to Veracyte?

Is VCYT or LMRI more profitable?

Do analysts rate VCYT or LMRI?

Does the media favor VCYT or LMRI?

Which has better valuation & earnings, VCYT or LMRI?

Summary

How does Lumexa Imaging compare to Privia Health Group?

Which has higher earnings and valuation, LMRI or PRVA?

Do institutionals & insiders believe in LMRI or PRVA?

Is LMRI or PRVA more profitable?

Do analysts recommend LMRI or PRVA?

Does the media prefer LMRI or PRVA?

Summary

How does Lumexa Imaging compare to Heartflow?

Do analysts prefer HTFL or LMRI?

Which has better earnings & valuation, HTFL or LMRI?

Is HTFL or LMRI more profitable?

Does the media prefer HTFL or LMRI?

Summary

How does Lumexa Imaging compare to GRAIL?

Is GRAL or LMRI more profitable?

Does the media prefer GRAL or LMRI?

Which has stronger valuation & earnings, GRAL or LMRI?

Do analysts prefer GRAL or LMRI?

Summary

How does Lumexa Imaging compare to Definium Therapeutics?

Do analysts prefer DFTX or LMRI?

Is DFTX or LMRI more profitable?

Does the media refer more to DFTX or LMRI?

Do insiders & institutionals have more ownership in DFTX or LMRI?

Which has higher earnings and valuation, DFTX or LMRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMRI vs. The Competition

Lumexa Imaging Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools